Deciphera Pharmaceuticals Stock Price Target and Analyst Ratings (NASDAQ:DCPH)

Analyst Price Target for DCPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$71.11

▲ +54.49% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Deciphera Pharmaceuticals in the last 3 months. The average price target is $71.11, with a high forecast of $91.00 and a low forecast of $49.00. The average price target represents a 54.49% upside from the last price of $46.03.

Buy

The current consensus among 9 investment analysts is to buy stock in Deciphera Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/5/2019

0 strong buy ratings
9 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/3/2019

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/1/2020

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/1/2020

0 strong buy ratings
11 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/30/2020

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/28/2020

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

12/27/2020

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/26/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
12/2/2020	Stifel Nicolaus	Initiated Coverage	Buy	$75.00	Medium	i
11/12/2020	SVB Leerink	Boost Price Target	Market Perform	$58.00 ➝ $70.00	Low	i
9/14/2020	SVB Leerink	Boost Price Target	Market Perform	$54.00 ➝ $58.00	Medium	i
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		High	i
8/5/2020	SVB Leerink	Lower Price Target	Market Perform	$55.00 ➝ $54.00	Low	i
6/12/2020	Guggenheim	Reiterated Rating	Buy	$70.00	High	i
5/18/2020	SunTrust Banks	Boost Price Target	Buy	$82.00 ➝ $91.00	Medium	i Rating by Robyn Karnauskas at SunTrust Banks, Inc.
5/18/2020	Barclays	Reiterated Rating	Buy	$80.00 ➝ $85.00	Medium	i
5/7/2020	Nomura Instinet	Downgrade	Buy ➝ Neutral	$84.00 ➝ $60.00	Low	i
5/6/2020	Nomura	Downgrade	Buy ➝ Neutral	$84.00 ➝ $60.00	Low	i
5/6/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	$50.00 ➝ $49.00	High	i
5/6/2020	HC Wainwright	Boost Price Target	Buy	$60.00 ➝ $80.00	High	i
4/29/2020	SunTrust Banks	Boost Price Target	Buy	$77.00 ➝ $82.00	Medium	i Rating by Robyn Karnauskas at SunTrust Banks, Inc.
4/29/2020	SVB Leerink	Boost Price Target	Hold	$50.00 ➝ $55.00	Medium	i
3/4/2020	Barclays	Initiated Coverage	Overweight	$70.00	High	i
1/22/2020	Piper Sandler	Reiterated Rating	Buy	$75.00	Low	i Rating by Christopher Raymond at Piper Sandler
1/21/2020	Nomura Securities	Boost Price Target	Buy	$57.00 ➝ $84.00	Low	i
1/15/2020	JMP Securities	Reiterated Rating	Buy	$70.00	Low	i Rating by Reni Benjamin at JMP Securities
1/10/2020	SunTrust Banks	Initiated Coverage	Buy	$77.00	Low	i Rating by Robyn Karnauskas at SunTrust Banks, Inc.
12/20/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$55.00 ➝ $75.00	Low	i Rating by Christopher Raymond at Piper Jaffray Companies
12/20/2019	Jefferies Financial Group	Boost Price Target	Buy	$53.00 ➝ $77.00	Medium	i Rating by Eun Yang at Jefferies Financial Group Inc.
11/5/2019	JMP Securities	Boost Price Target	Outperform ➝ Market Outperform	$45.00 ➝ $54.00	Low	i
10/29/2019	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$29.00 ➝ $34.00	Medium	i Rating by A. Berens at SVB Leerink LLC
10/22/2019	JMP Securities	Initiated Coverage	Outperform		Low	i
10/3/2019	HC Wainwright	Initiated Coverage	Buy	$60.00	High	i Rating by A. Fein at HC Wainwright
9/30/2019	Piper Jaffray Companies	Set Price Target	Buy	$55.00	High	i Rating by Christopher Raymond at Piper Jaffray Companies
9/30/2019	Jefferies Financial Group	Initiated Coverage	Buy	$47.00	High	i
8/14/2019	SunTrust Banks	Boost Price Target	Positive ➝ Buy	$60.00	Low	i
8/14/2019	SVB Leerink	Reiterated Rating	Underperform ➝ Positive	$20.00 ➝ $29.00	High	i
8/14/2019	Cantor Fitzgerald	Boost Price Target	Overweight	$43.00 ➝ $55.00	High	i
8/14/2019	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $65.00	Medium	i
8/13/2019	Guggenheim	Boost Price Target	Buy	$44.00 ➝ $66.00	High	i
7/18/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy	$42.00	Low	i
6/3/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$50.00 ➝ $55.00	High	i
3/15/2019	Canaccord Genuity	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $50.00	High	i
1/1/2019	B. Riley	Downgrade	Buy ➝ Neutral		High	i
12/31/2018	B. Riley	Initiated Coverage	Neutral ➝ Buy	$27.00 ➝ $34.00	High	i Rating by G. Zavoico at B. Riley
12/20/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$53.00	Medium	i Rating by Charles Duncan at Cantor Fitzgerald
11/16/2018	SVB Leerink	Lower Price Target	Underperform	$28.00 ➝ $20.00	Medium	i Rating by A. Berens at SVB Leerink LLC
10/3/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$53.00	Medium	i Rating by Charles Duncan at Cantor Fitzgerald
9/24/2018	SVB Leerink	Initiated Coverage	Underperform ➝ Underperform	$28.00	Low	i Rating by A. Berens at SVB Leerink LLC
9/17/2018	Guggenheim	Initiated Coverage	Buy		High	i
9/6/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$53.00	High	i Rating by Charles Duncan at Cantor Fitzgerald
8/29/2018	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$47.00	Medium	i
8/22/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$53.00	Medium	i Rating by C. Duncan at Cantor Fitzgerald
8/13/2018	Canaccord Genuity	Set Price Target	Buy	$55.00	Low	i Rating by Arlinda Lee at Canaccord Genuity
8/7/2018	Canaccord Genuity	Initiated Coverage	Buy	$55.00	Low	i
7/5/2018	SunTrust Banks	Initiated Coverage	Buy		High	i
6/19/2018	JMP Securities	Boost Price Target	Outperform	$65.00	Low	i
6/19/2018	B. Riley	Downgrade	Buy ➝ Neutral	$43.00	Medium	i Rating by M. Kumar at B. Riley
6/12/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$50.00	Low	i
6/4/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $33.00	High	i
5/9/2018	B. Riley	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $43.00	High	i Rating by M. Kumar at B. Riley
2/16/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$43.00	High	i Rating by M. Kumar at B. Riley
10/23/2017	Nomura Securities	Initiated Coverage	Buy ➝ Buy	$57.00	N/A	i
10/23/2017	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$35.00	N/A	i
10/23/2017	Nomura Instinet	Initiated Coverage	Buy	$57.00	N/A	i
10/23/2017	JMP Securities	Initiated Coverage	Mkt Outperform ➝ Outperform	$38.00	N/A	i
10/23/2017	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$30.00	N/A	i

(Data available from 1/27/2016 forward)

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $46.03

$45.77

$48.20

50 Day Range

MA: $54.48

$46.76

$61.08

52 Week Range

Now: $46.03

$33.10

$71.11

Volume

398,791 shs

Average Volume

410,381 shs

Market Capitalization

$2.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Deciphera Pharmaceuticals?

The following Wall Street research analysts have issued reports on Deciphera Pharmaceuticals in the last year: Barclays PLC, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Nomura, Nomura Instinet, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, and Zacks Investment Research.

What is the current price target for Deciphera Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Deciphera Pharmaceuticals in the last year. Their average twelve-month price target is $71.11, suggesting a possible upside of 54.5%. SunTrust Banks, Inc. has the highest price target set, predicting DCPH will reach $91.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $49.00 for Deciphera Pharmaceuticals in the next year.

What is the current consensus analyst rating for Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals currently has 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DCPH will outperform the market and that investors should add to their positions of Deciphera Pharmaceuticals.

What other companies compete with Deciphera Pharmaceuticals?

Other companies that are similar to Deciphera Pharmaceuticals include Mirati Therapeutics, Zai Lab, Bausch Health Companies, Jazz Pharmaceuticals, Ionis Pharmaceuticals, Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, Ascendis Pharma A/S, ACADIA Pharmaceuticals, BridgeBio Pharma, United Therapeutics, Sarepta Therapeutics, Galapagos, Allakos and TG Therapeutics.

How do I contact Deciphera Pharmaceuticals' investor relations team?

Deciphera Pharmaceuticals' physical mailing address is 200 SMITH STREET, Waltham MA, 02451. The company's listed phone number is 781-209-6400 and its investor relations email address is [email protected] The official website for Deciphera Pharmaceuticals is www.deciphera.com.

NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for DCPH

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Deciphera Pharmaceuticals?

What is the current price target for Deciphera Pharmaceuticals?

What is the current consensus analyst rating for Deciphera Pharmaceuticals?

What other companies compete with Deciphera Pharmaceuticals?

How do I contact Deciphera Pharmaceuticals' investor relations team?